Compare Amphastar Pharmaceuticals Inc (AMPH) vs Banco Santander SA (SAN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Banco Santander SA — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.72 (market cap $826.08M), while Banco Santander SA trades at $13.75 (market cap $197.91B). The key difference: Banco Santander SA is far larger — about 239.6× Amphastar Pharmaceuticals Inc's market cap, and Banco Santander SA pays a 2.01% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | SAN | |
|---|---|---|
Market Cap | $826.08M | $197.91B |
Sector | Health | Financials |
52-Week High | $30.81 | $14.37 |
52-Week Low | $16.87 | $8.31 |
Enterprise Value | $1.22B | — |
Dividend Yield | — | 2.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
Banco Santander (SAN) trades at $13.87, up 0.58% today, with a bullish technical signal from moving averages. The company reported $14.10B net income for 2025 with a 23.49% margin, though recent quarterly EPS results missed expectations. Analyst consensus is 64% buy, supported by news of Santander becoming Spain's most valuable company and its AI-driven efficiency initiatives.
Outlook is cautiously optimistic with strong profitability and strategic acquisitions, but risks include consecutive EPS misses, a significant net cash outflow trend, and regulatory scrutiny in Spain. The stock's valuation appears reasonable with a P/E of 13.78, offering potential upside if operational improvements materialize.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Banco Santander SA
Santander's focus is on retail and commercial banking. Latin America is geographically the largest operation, with Brazil by far the largest. Its continental European business is still mainly Iberian. Santander's U.K. presence is the result of the acquisition of building society Abbey. In the U.S., Santander operates a vehicle finance business and a regional bank focused on the Northeastern states.
Read more on SAN →
